Drug intelligence / Profile preview

Klf10 siRNA

Development stage
Preclinical
Lead developer
National Health Research Institutes
Modality
Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intravenous
01

Overview

Klf10 siRNA is a small interfering RNA (siRNA) designed to silence the expression of Krüpple-like factor 10 (Klf10), a transcription factor that acts as an early response gene in the TGFβ signaling pathway. Research conducted by the National Health Research Institutes (NHRI) in Taiwan has utilized Klf10 siRNA to demonstrate that the loss of Klf10 promotes epithelial-mesenchymal transition (EMT) and distant metastasis in pancreatic cancer. Mechanistically, silencing Klf10 leads to the downregulation of Sirt 6, which in turn increases the expression of glycolytic enzymes like PKM2 via HIF-1α, thereby enhancing the migratory and invasive capabilities of cancer cells. It is primarily employed as a research tool in preclinical models to study the molecular pathogenesis of pancreatic adenocarcinoma and evaluate Klf10 as a potential prognostic and therapeutic biomarker.

Other names
Klf10 mRNA silencingKlf-10 mRNA silencingKlf 10 mRNA silencingKrüpple-like factor 10 siRNAKLF10-siRNAKLF-10-siRNAKLF 10-siRNA
02

Targets

KLF10

Beyond the preview

Go deeper on Klf10 siRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Klf10 siRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call